Drugs / EP-9001A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05278611 | Mar → Sep 2022 | — | Chengdu Easton Biopharmaceuticals Co,Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EP-9001A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05278611 ↗ |
| Route | Subcutaneous | “subcutaneous (SC) administered EP-9001A” NCT05278611 ↗ |
| Target | NGF | “EP-9001A is a humanized monoclonal antibody targeting NGF” NCT05278611 ↗ |